Directed evolution of single-chain Fv for cytoplasmic expression using the β-galactosidase complementation assay results in proteins highly susceptible to protease degradation and aggregation

Microbial Cell Factories

Volumn 3, Issue , 2004, Pages

  Philibert, Pascal ^a   Martineau, Pierre ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; ENDOPEPTIDASE LA; HYBRID PROTEIN; PROTEINASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL CELL; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; ENZYME ACTIVITY; ENZYME DEFICIENCY; ESCHERICHIA COLI; EVOLUTION; GENE LIBRARY; GENE MUTATION; GENETIC COMPLEMENTATION; GENETIC SELECTION; HYPOTHESIS; MOLECULAR CLONING; MUTAGENESIS; NONHUMAN; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; WILD TYPE;

ESCHERICHIA COLI;

EID: 13644250279     PISSN: 14752859     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2859-3-16     Document Type: Article

References (57)

1. Souriau C, Hudson PJ: Recombinant antibodies for cancer diagnosis and therapy. Expert Opin Biol Ther 2003, 3: 05-18.
2. Glockshuber R, Schmidt T, Pluckthun A: The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli. Biochemistry 1992, 31:1270-9.
3. Proba K, Honegger A, Pluckthun A: A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding. J Mol Biol 1997, 265:161-72.
4. Martineau P, Betton JM: In vitro folding and thermodynamic stability of an antibody fragment selected in vivo for high expression levels in Escherichia coli cytoplasm. J Mol Biol 1999, 292: 21-9.
5. Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, Wong WL, Rowland AM, Kotts CE, Carver ME: High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology (N Y) 1992, 10:163-7.
6. Guo JQ, You SY, Li L, Zhang YZ, Huang JN, Zhang CY: Construction and high-level expression of a single-chain Fv antibody fragment specific for acidic isoferritin in Escherichia coli. J Biotechnol 2003, 102:177-89.
7. Buchner J, Rudolph R: Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli. Biotechnology (N Y) 1991, 9:157-62.
8. Ritz D, Lim J, Reynolds CM, Poole LB, Beckwith J: Conversion of a peroxiredoxin into a disulfide reductase by a triplet repeat expansion. Science 2001, 294:158-60.
9. Venturi M, Seifert C, Hunte C: High level production of functional antibody Fab fragments in an oxidizing bacterial cytoplasm. J Mol Biol 2002, 315:1-8.
10. Levy R, Weiss R, Chen G, Iverson BL, Georgiou G: Production of correctly folded Fab antibody fragment in the cytoplasm of Escherichia coli trxB gor mutants via the coexpression of molecular chaperones. Protein Expr Purif 2001, 23:338-47.
11. Jurado P, Ritz D, Beckwith J, Lorenzo V, Fernandez LA: Production of functional single-chain Fv antibodies in the cytoplasm of Escherichia coli. J Mol Biol 2002, 320:1-10.
12. Zhang D, Murakami A, Johnson RP, Sui J, Cheng J, Bai J, Marasco WA: Optimization of ex vivo activation and expansion of macaque primary CD4-enriched peripheral blood mononuclear cells for use in anti-HIV immunotherapy and gene therapy strategies. J Acquir Immune Defic Syndr 2003, 32:245-54.
13. Hyland S, Beerli RR, Barbas CF, Hynes NE, Wels W: Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor. Oncogene 2003, 22:1557-67.
14. Cohen PA: Intrabodies. Targeting scFv expression to eukaryotic intracellular compartments. Methods Mol Biol 2002, 178:367-78.
15. Dauvillier S, Merida P, Visintin M, Cattaneo A, Bonnerot C, Dariavach P: Intracellular single-chain variable fragments directed to the Src homology 2 domains of Syk partially inhibit Fc epsilon RI signaling in the RBL-2H3 cell line. J Immunol 2002, 169: 274-83.
16. Lobato MN, Rabbitts TH: Intracellular antibodies and challenges facing their use as therapeutic agents. Trends Mol Med 2003, 9:390-6.
17. Jones DA, Fitzpatrick FA: Genomics and the discovery of new drug targets. Curr Opin Chem Biol 1999, 3:71-6.
18. Waldo GS: Genetic screens and directed evolution for protein solubility. Curr Opin Chem Biol 2003, 7:33-8.
19. Waldo GS, Standish BM, Berendzen J, Terwilliger TC: Rapid protein-folding assay using green fluorescent protein. Nat Biotechnol 1999, 17:691-5.
20. Maxwell KL, Mittermaier AK, Forman-Kay JD, Davidson AR: A simple in vivo assay for increased protein solubility. Protein Sci 1999, 8:1908-11.
21. Wigley WC, Stidham RD, Smith NM, Hunt JF, Thomas PJ: Protein solubility and folding monitored in vivo by structural complementation of a genetic marker protein. Nat Biotechnol 2001, 19:131-6.
22. Welply JK, Fowler AV, Zabin I: Beta-Galactosidase alpha-complementation. Overlapping sequences. J Biol Chem 1981, 256:6804-10.
23. Ullmann A, Jacob F, Monod J: Characterization by in vitro complementation of a peptide corresponding to an operator-proximal segment of the beta-galactosidase structural gene of Escherichia coli. J Mol Biol 1967, 24:339-43.
24. Langley KE, Zabin I: Beta-Galactosidase alpha complementation: properties of the complemented enzyme and mechanism of the complementation reaction. Biochemistry 1976, 15: 866-75.
25. Yang JK, Park MS, Waldo GS, Suh SW: Directed evolution approach to a structural genomics project: Rv2002 from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2003, 100:455-60.
26. Pedelacq JD, Piltch E, Liong EC, Berendzen J, Kim CY, Rho BS, Park MS, Terwilliger TC, Waldo GS: Engineering soluble proteins for structural genomics. Nat Biotechnol 2002, 20:927-32.
27. Sieber V, Martinez CA, Arnold FH: Libraries of hybrid proteins from distantly related sequences. Nat Biotechnol 2001, 19:456-60.
28. Martineau P, Jones P, Winter G: Expression of an antibody fragment at high levels in the bacterial cytoplasm. J Mol Biol 1998, 280:117-27.
29. Laden JC, Philibert P, Torreilles F, Pugniere M, Martineau P: Expression and folding of an antibody fragment selected in vivo for high expression levels in Escherichia coli cytoplasm. Res Microbiol 2002, 153:469-74.
30. Miller JH: A short course in bacterial genetics Cold Spring Harbor Laboratory Press; 1992.
31. Holmes MA, Buss TN, Foote J: Structural effects of framework mutations on a humanized anti-lysozyme antibody. J Immunol 2001, 167:296-301.
32. Neri D, Natali PG, Petrul H, Soldani P, Nicotra MR, Vola R, Rivella A, Creighton AM, Neri P, Mariani M: Recombinant anti-human melanoma antibodies are versatile molecules. J Invest Dermatol 1996, 107:164-70.
33. Chung CH, Goldberg AL: The product of the lon (capR) gene in Escherichia coli is the ATP-dependent protease, protease La. Proc Natl Acad Sci U S A 1981, 78:4931-5.
34. Herman C, D'Ari R: Proteolysis and chaperones: the destruction/reconstruction dilemma. Curr Opin Microbiol 1998, 1:204-209.
35. saiSree L, Reddy M, Gowrishankar J: IS186 insertion at a hot spot in the lon promoter as a basis for lon protease deficiency of Escherichia coli B: identification of a consensus target sequence for IS186 transposition. J Bacteriol 2001, 183:6943-6.
36. Juers DH, Jacobson RH, Wigley D, Zhang XJ, Huber RE, Tronrud DE, Matthews BW: High resolution refinement of beta-galactosidase in a new crystal form reveals multiple metal-binding sites and provides a structural basis for alpha-complementation. Protein Sci 2000, 9:1685-99.
37. Corchero JL, Villaverde A: Tolerance of escherichia coli beta-galactosidase c-terminus to different-sized fusions. Biotechnol Bioeng 1999, 64:644-649.
38. Planson A, Guijarro JI, Goldberg ME, Chaffotte AF: Assistance of maltose binding protein to the in vivo folding of the disulfiderich c-terminal fragment from plasmodium falciparum merozoite surface protein 1 expressed in escherichia coli. Biochemistry 2003, 42:13202-13211.
39. Davis GD, Elisee C, Newham DM, Harrison RG: New fusion protein systems designed to give soluble expression in escherichia coli. Biotechnol Bioeng 1999, 65:382-388.
40. Sachdev D, Chirgwin JM: Solubility of proteins isolated from inclusion bodies is enhanced by fusion to maltose-binding protein or thioredoxin. Protein Expr Purif 1998, 12:122-132.
41. Studier FW, Rosenberg AH, Dunn JJ, Dubendorff JW: Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol 1990, 185:60-89.
42. Parsell DA, Sauer RT: The structural stability of a protein is an important determinant of its proteolytic susceptibility in Escherichia coli. J Biol Chem 1989, 264:7590-5.
43. Betton JM, Sassoon N, Hofnung M, Laurent M: Degradation versus aggregation of misfolded maltose-binding protein in the periplasm of Escherichia coli. J Biol Chem 1998, 273:8897-902.
44. Kiefhaber T, Rudolph R, Kohler HH, Buchner J: Protein aggregation in vitro and in vivo: a quantitative model of the kinetic competition between folding and aggregation. Biotechnology (N Y 1991, 9:825-9.
45. Goldberg ME, Rudolph R, Jaenicke R: A kinetic study of the competition between renaturation and aggregation during the refolding of denatured-reduced egg white lysozyme. Biochemistry 1991, 30: 790-7.
46. Jaenicke R: Folding and association versus misfolding and aggregation of proteins. Philos Trans R Soc Lond B Biol Sci 1995, 348:97-105.
47. Mitraki A, Danner M, King J, Seckler R: Temperature-sensitive mutations and second-site suppressor substitutions affect folding of the P22 tailspike protein in vitro. J Biol Chem 1993, 268:20071-5.
48. Kapust RB, Waugh DS: Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused. Protein Sci 1999, 8: 668-1674.
49. Nieba L, Honegger A, Krebber C, Pluckthun A: Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scfv fragment. Protein Eng 1997, 10:435-444.
50. Schwalbach G, Sibler AP, Choulier L, Deryckere F, Weiss E: Production of fluorescent single-chain antibody fragments in Escherichia coli. Protein Expr Purif 2000, 18:121-32.
51. Proba K, Worn A, Honegger A, Pluckthun A: Antibody scFv fragments without disulfide bonds made by molecular evolution. J Mol Biol 1998, 275:245-53.
52. Visintin M, Tse E, Axelson H, Rabbitts TH, Cattaneo A: Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc Natl Acad Sci U S A 1999, 96:11723-8.
53. Auf der Maur A, Escher D, Barberis A: Antigen-independent selection of stable intracellular single-chain antibodies. FEBS Lett 2001, 508:407-12.
54. Grossman AD, Burgess RR, Walter W, Gross CA: Mutations in the Ion gene of E. coli K12 phenotypically suppress a mutation in the sigma subunit of RNA polymerase. Cell 1983, 32:151-9.
55. Singer M, Baker TA, Schnitzler G, Deischel SM, Goel M, Dove W, Jaacks KJ, Grossman AD, Erickson JW, Gross CA: A collection of strains containing genetically linked alternating antibiotic resistance elements for genetic mapping of Escherichia coli. Microbiol Rev 1989, 53:1-24.
56. Martineau P: Error-prone polymerase chain reaction for modification of scFvs. Methods Mol Biol 2002, 178:287-94.
57. Martin AC: Accessing the Kabat antibody sequence database by computer. Proteins 1996, 25:130-3.